Amneal Enterprises has fueled its growth through mergers and acquisitions—with seamless integration of people and processes. The leaders within the consortium are able to drive maximum quality, efficiency and effectiveness by enrolling each team member in our core philosophy and empowering each to do their best. This exemplary advisory team provides the guidance needed to enable each entity Amneal Enterprises touches to obtain its highest potential.
A true entrepreneur, Chirag has over two decades of experience in core positions such as finance, corporate planning, business development, and information technology. He established two technology companies and logged over eight years in senior-level positions at three Fortune-50 corporations before co-founding Amneal Pharmaceuticals. Chirag received Bachelor’s degrees in Business Administration and Accounting from H.A. College of Commerce in India and New Jersey City University, qualifying for CPA certification in 1993.
Currently, Chirag leads corporate development and strategy, finance, administration, sales and marketing as President and Co-founder of Amneal Pharmaceuticals. He spearheaded the generic manufacturer’s record-breaking growth, successfully identifying, executing and completing four acquisitions in less than three years and overseeing their seamless integration. His vision of rapid yet disciplined and deliberate growth—so wildly successful at Amneal Pharmaceuticals—is an essential element in the achievement and future success of Amneal Enterprises.
Chintu started his career in 1994, after receiving his Bachelors in Pharmacy from Rutgers College of Pharmacy. He was a pharmacist and manager with Eckerd Drugs—where he received numerous awards -until his departure in 2002. Passionate about building an innovative pharmaceutical company based on quality and integrity, Chintu co-founded Amneal Pharmaceuticals.
Today, Chintu is CEO of Amneal Pharmaceuticals, heading up research and development operations, quality management, manufacturing, regulatory affairs and intellectual property. His leadership has marshaled the successful application and approval of all ANDAs, ensuring a 100% success rate of scale-up from lab to production quantities. Chintu’s unwavering commitment to quality, dedication to unparalleled R&D and stringent regulatory compliance has led the company from its modest beginnings to celebrated success as the 9th largest U.S. generic drug supplier with a diversified and rapidly growing portfolio of 40 products. He possesses a keen ability to wholly integrate acquisitions to achieve maximum efficiency while instilling a spirit of empowerment and collaboration in each newly aligned organization. He drives accountability, keeps the primary goal clearly in focus as well as everyone aligned and committed to the vision. The innate qualities Chintu brings to Amneal Enterprises are indispensible to the emergent group.
Jack has been a premier healthcare strategist and consultant for over 30 years. He holds a B.S. degree from McGill University, an MBA from the University of Western Ontario and is an alumnus of McKinsey & Co. As Sr. VP of Extendicare Ltd, he operated one of North America’s largest nursing home, diagnostic lab and home care chains. As president of the consulting firm of Bogart, Delafield and Ferrier, he provided strategic consulting services to major pharmaceutical companies (Pfizer, Merck, Rorer, Upjohn, Searle, and Baxter) as well as numerous biotech firms. For over a decade, through 2006, his strategic consulting services were retained on an exclusive basis by the senior management of Pfizer Inc.
Jack’s direct experience has involved multiple aspects of healthcare ranging from public health policy, insurance, institutional and home services, pharmaceuticals, diagnostics, biotech, devices, advertising, medical education and over-the-counter products. He has provided counsel and expert opinion to government agencies, medical associations and think tanks throughout North America. Jack contributes this global, industry-encompassing perspective toward the success of Amneal Enterprises.
Dr. Hariharan Dr. Hariharan spent 14 years with Forest Labs. Starting as a manager in the Bio Analytical department and working his way up to Senior VP & Corporate Officer, he became a legacy in the company and is highly regarded as the key executive who transformed their R&D strategy. Shankar then served as Chief Scientific Officer and EVP of Par Pharmaceutical Companies, Inc. where he created a brand product development division, identified products for internal development or in-licensing, successfully built internal expertise in ANDAs and redirected the product selection strategy to value-added offerings.
Upon leaving Par, Dr. Hariharan co-founded and held the President and CEO roles for two companies dedicated to developing and commercializing products for dermatology applications. Dr. Hariharan received his Ph.D. from Northeastern University’s School of Pharmacy and Masters and Bachelor of Pharmacy degrees from Banaras Hindu University in Varanasi, India.
Most recently, Dr. Hariharan acts as Chief Scientific Officer and Executive Vice President at Amneal Pharmaceuticals. His depth of R&D experience, proven results and strong leadership skills bring tremendous value to Amneal Enterprises as the organization extends its reach in both generic and specialty pharmaceuticals.
Jim brings 30 years of Fortune 100-level sales leadership, strategic planning and organizational development experience to Amneal Enterprises. This includes his dynamic tenure as EVP-Retail Sales & Strategic Accounts for Bergen Brunswig Drug Company/AmerisourceBergen Drug Company. His unique approach to driving customer value and focusing on mutual value creation with customers were key factors in growing the business at almost twice the pace of the industry. Before entering the pharmaceuticals industry, Jim enjoyed an 18-year career with Marriott International Corporation culminating in the role of Regional Vice President-Sales & Marketing for the Western US and Canada.
In his current role as EVP, Sales & Marketing at Amneal Pharmaceuticals, Jim’s candid and collaborative style, charismatic leadership, and veteran sales acumen has taken the generic firm from initial label launch to industry-leading growth across all customers, market segments and products. Jim has led the Amneal sales team to prominence in the industry, earning the company five major awards within an 18-month period—four from the largest pharmaceutical wholesalers/distributors and one, the prestigious DIANA, from the Healthcare Distribution Management Association.
Bob holds a J.D. from Brooklyn Law School and an LLM in Taxation from NYU School of Law. He brings to Amneal Enterprises nearly 20 years of experience in the pharmaceutical industry with diverse experience in the areas of M & A, domestic and international joint ventures and strategic alliances, product licensing, settlement of Paragraph IV litigation, and a broad range of regulatory matters. Mr. Loewenstein was previously a member of the law firm Budd Larner, P.C. in Short Hills, NJ, where he was head of the firm’s corporate generic pharmaceuticals practice.
Since the fall of 2005, Mr. Loewenstein has represented Amneal Pharmaceuticals in virtually all of its business activities, including the acquisition of Akyma Pharmaceuticals, KVD Pharmaceuticals and Interpharm, Inc. He has been instrumental in the birth and growth of Amneal Enterprises, where he provides council for mergers, acquisitions, joint ventures, product collaboration arrangements, product and technology in-licensing and out-licensing agreements along with acquisition and dispositions of U.S. product portfolios.
Gautam brings a broad range of financial advisory experience to Amneal Enterprises. His experience as Managing Director with Lazard Investment Banking Group included responsibility for numerous financing and restructuring assignments with many of the firm’s largest clients. Gautam also led Lazard’s U.S. private equity coverage practice and was a member of the firm’s healthcare team focused on advising pharmaceutical and medical technology companies. Prior to joining Lazard, Gautam worked on financial advisory and high yield debt financing transactions as an analyst at Donaldson, Lufkin & Jenrette Securities Corporation.
Gautam currently advises Amneal Enterprises on its business development strategy, including mergers, acquisitions, joint ventures and alliances. Gautam holds a B.S. in Engineering from Harvey Mudd College, a B.A. in Management-Engineering from Claremont McKenna College, as well as an M.S. in Finance from the London School of Economics and an M.B.A. from the University of Chicago.
Diane joined Amneal Enterprises with over a decade of finance and accounting experience. After a start in public accounting at Arthur Anderson, Diane moved into pharmaceuticals moving through top finance positions with Pliva, Barr, Bradley and the PharmaDerm division of Fougera. She then capitalized on her rich experience opening a successful consulting practice before joining the Amneal Enterprises group in December of 2010.
In her current position, Ms. Grube is responsible for all finance and accounting functions at Amneal Enterprises and acts as financial advisor when called on by the alliance members. Diane graduated Montclair State with a B. S. in Accounting and earned her MBA in Finance from Rutgers University.
Charmaine joined Amneal Enterprises in September 2011 with over 16 years of managerial and merger expertise across domestic and international locations. She has extensive experience in developing staffing and retention programs as well as compensation and benefit systems, employee training and development, and human resource policies and procedures.
Charmaine serves as the Director for Human Resource Services at Amneal Enterprises overseeing HR services for the company and supporting its alliance members as required. Prior to joining Amneal, Charmaine worked in leadership roles within the information technology industry where she served as the Director of Human Resources at Niteo Partners Inc. (an NEC company) and at Exinom Technologies Inc.